W World Corp.
WWHC
Other OTC0.80
USD
-0.20
- -
W World Corp.
WWHC
(Other OTC)
Recent
price
0.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- W World Corp. (WWHC) operates as a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics targeting metabolic and nervous system disorders, including those of the brain-gut axis; pain and inflammation; autoimmune conditions; gout; irritable bowel syndrome; oncology; immunology; ophthalmology; infectious diseases; and central nervous system disorders. The company offers lead clinical-stage compounds such as Levotofisopam, a non-sedating agent for gout treatment, and Dextofisopam, a non-serotonergic agent that has completed Phase IIa and Phase IIb trials for irritable bowel syndrome; it also provides oncology medicines including hormone therapy, targeted therapies and immunotherapies, antibiotics for bacterial infections, antimalarials, cancer maintenance medications, and generics like Lisinopril (Prinivil/Zestril) for blood pressure management, heart failure and kidney protection. Founded in 1990 and headquartered at 3609 Hammerkop Drive in North Las Vegas, Nevada, W World Corp. maintains operations primarily in the United States with a pipeline encompassing preclinical and clinical candidates; the company emphasizes sustainable development goals such as good health, innovation, responsible production and partnerships, alongside ethical supply chain management and third-party risk mitigation. Recent activities reflect a strategic pivot toward diversified pharmaceutical offerings, including emphasized cancer diagnostics, diabetes management and expanded biotech solutions in oncology and immunology as highlighted on its website; no major acquisitions, funding rounds or partnerships have been publicly reported in the last one to two years.